Use of calcium channel blockers and breast cancer risk in the women's health initiative

Theodore M. Brasky, Jessica L. Krok-Schoen, Jingmin Liu, Rowan T. Chlebowski, Jo L. Freudenheim, Sayeh Lavasani, Karen L. Margolis, Lihong Qi, Kerryn W. Reding, Peter G. Shields, Michael S. Simon, Jean Wactawski-Wende, Ange Wang, Catherine Womack, Jo Ann E. Manson

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: Use of calcium channel blockers (CCBs) has been associated with increased risk of breast cancer in some, but not all, studies. Differences in reported associations from prior studies may be due, in part, to inadequate control of confounding factors. Methods: Participants were 28, 561 postmenopausal women from the Women's Health Initiative who reported use of either CCBs or other antihypertensive medications (AHMs) at baseline; 1, 402 incident breast cancer cases were diagnosed during 12 years of follow-up. Adjusted Cox regression models were used to estimate HRs and 95% confidence intervals (CI) for the associations between CCB use relative to other AHMuse and breast cancer risk. Results: Use of CCBs was not associated with breast cancer risk (HR, 1.06; 95% CI, 0.94-1.20) relative to use of other AHMs. Associations approximated the null value when CCBs were considered by duration of use, length of action, or drug class. Conclusions: We provide additional evidence that CCBs do not influence breast cancer risk in postmenopausal women. Impact: The results from this study, which includes strong control for potential confounding factors, cast doubt on increases in risk with CCBs. Cancer Epidemiol Biomarkers Prev; 26(8); 1345-8.

Original languageEnglish (US)
Pages (from-to)1345-1348
Number of pages4
JournalCancer Epidemiology Biomarkers and Prevention
Volume26
Issue number8
DOIs
StatePublished - Aug 1 2017

Fingerprint

Calcium Channel Blockers
Women's Health
Breast Neoplasms
Antihypertensive Agents
Confidence Intervals
Tumor Biomarkers
Proportional Hazards Models
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this

Brasky, T. M., Krok-Schoen, J. L., Liu, J., Chlebowski, R. T., Freudenheim, J. L., Lavasani, S., ... Manson, J. A. E. (2017). Use of calcium channel blockers and breast cancer risk in the women's health initiative. Cancer Epidemiology Biomarkers and Prevention, 26(8), 1345-1348. https://doi.org/10.1158/1055-9965.EPI-17-0096

Use of calcium channel blockers and breast cancer risk in the women's health initiative. / Brasky, Theodore M.; Krok-Schoen, Jessica L.; Liu, Jingmin; Chlebowski, Rowan T.; Freudenheim, Jo L.; Lavasani, Sayeh; Margolis, Karen L.; Qi, Lihong; Reding, Kerryn W.; Shields, Peter G.; Simon, Michael S.; Wactawski-Wende, Jean; Wang, Ange; Womack, Catherine; Manson, Jo Ann E.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 26, No. 8, 01.08.2017, p. 1345-1348.

Research output: Contribution to journalArticle

Brasky, TM, Krok-Schoen, JL, Liu, J, Chlebowski, RT, Freudenheim, JL, Lavasani, S, Margolis, KL, Qi, L, Reding, KW, Shields, PG, Simon, MS, Wactawski-Wende, J, Wang, A, Womack, C & Manson, JAE 2017, 'Use of calcium channel blockers and breast cancer risk in the women's health initiative', Cancer Epidemiology Biomarkers and Prevention, vol. 26, no. 8, pp. 1345-1348. https://doi.org/10.1158/1055-9965.EPI-17-0096
Brasky, Theodore M. ; Krok-Schoen, Jessica L. ; Liu, Jingmin ; Chlebowski, Rowan T. ; Freudenheim, Jo L. ; Lavasani, Sayeh ; Margolis, Karen L. ; Qi, Lihong ; Reding, Kerryn W. ; Shields, Peter G. ; Simon, Michael S. ; Wactawski-Wende, Jean ; Wang, Ange ; Womack, Catherine ; Manson, Jo Ann E. / Use of calcium channel blockers and breast cancer risk in the women's health initiative. In: Cancer Epidemiology Biomarkers and Prevention. 2017 ; Vol. 26, No. 8. pp. 1345-1348.
@article{d3d864578447488a8f4944749b0202f4,
title = "Use of calcium channel blockers and breast cancer risk in the women's health initiative",
abstract = "Background: Use of calcium channel blockers (CCBs) has been associated with increased risk of breast cancer in some, but not all, studies. Differences in reported associations from prior studies may be due, in part, to inadequate control of confounding factors. Methods: Participants were 28, 561 postmenopausal women from the Women's Health Initiative who reported use of either CCBs or other antihypertensive medications (AHMs) at baseline; 1, 402 incident breast cancer cases were diagnosed during 12 years of follow-up. Adjusted Cox regression models were used to estimate HRs and 95{\%} confidence intervals (CI) for the associations between CCB use relative to other AHMuse and breast cancer risk. Results: Use of CCBs was not associated with breast cancer risk (HR, 1.06; 95{\%} CI, 0.94-1.20) relative to use of other AHMs. Associations approximated the null value when CCBs were considered by duration of use, length of action, or drug class. Conclusions: We provide additional evidence that CCBs do not influence breast cancer risk in postmenopausal women. Impact: The results from this study, which includes strong control for potential confounding factors, cast doubt on increases in risk with CCBs. Cancer Epidemiol Biomarkers Prev; 26(8); 1345-8.",
author = "Brasky, {Theodore M.} and Krok-Schoen, {Jessica L.} and Jingmin Liu and Chlebowski, {Rowan T.} and Freudenheim, {Jo L.} and Sayeh Lavasani and Margolis, {Karen L.} and Lihong Qi and Reding, {Kerryn W.} and Shields, {Peter G.} and Simon, {Michael S.} and Jean Wactawski-Wende and Ange Wang and Catherine Womack and Manson, {Jo Ann E.}",
year = "2017",
month = "8",
day = "1",
doi = "10.1158/1055-9965.EPI-17-0096",
language = "English (US)",
volume = "26",
pages = "1345--1348",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "8",

}

TY - JOUR

T1 - Use of calcium channel blockers and breast cancer risk in the women's health initiative

AU - Brasky, Theodore M.

AU - Krok-Schoen, Jessica L.

AU - Liu, Jingmin

AU - Chlebowski, Rowan T.

AU - Freudenheim, Jo L.

AU - Lavasani, Sayeh

AU - Margolis, Karen L.

AU - Qi, Lihong

AU - Reding, Kerryn W.

AU - Shields, Peter G.

AU - Simon, Michael S.

AU - Wactawski-Wende, Jean

AU - Wang, Ange

AU - Womack, Catherine

AU - Manson, Jo Ann E.

PY - 2017/8/1

Y1 - 2017/8/1

N2 - Background: Use of calcium channel blockers (CCBs) has been associated with increased risk of breast cancer in some, but not all, studies. Differences in reported associations from prior studies may be due, in part, to inadequate control of confounding factors. Methods: Participants were 28, 561 postmenopausal women from the Women's Health Initiative who reported use of either CCBs or other antihypertensive medications (AHMs) at baseline; 1, 402 incident breast cancer cases were diagnosed during 12 years of follow-up. Adjusted Cox regression models were used to estimate HRs and 95% confidence intervals (CI) for the associations between CCB use relative to other AHMuse and breast cancer risk. Results: Use of CCBs was not associated with breast cancer risk (HR, 1.06; 95% CI, 0.94-1.20) relative to use of other AHMs. Associations approximated the null value when CCBs were considered by duration of use, length of action, or drug class. Conclusions: We provide additional evidence that CCBs do not influence breast cancer risk in postmenopausal women. Impact: The results from this study, which includes strong control for potential confounding factors, cast doubt on increases in risk with CCBs. Cancer Epidemiol Biomarkers Prev; 26(8); 1345-8.

AB - Background: Use of calcium channel blockers (CCBs) has been associated with increased risk of breast cancer in some, but not all, studies. Differences in reported associations from prior studies may be due, in part, to inadequate control of confounding factors. Methods: Participants were 28, 561 postmenopausal women from the Women's Health Initiative who reported use of either CCBs or other antihypertensive medications (AHMs) at baseline; 1, 402 incident breast cancer cases were diagnosed during 12 years of follow-up. Adjusted Cox regression models were used to estimate HRs and 95% confidence intervals (CI) for the associations between CCB use relative to other AHMuse and breast cancer risk. Results: Use of CCBs was not associated with breast cancer risk (HR, 1.06; 95% CI, 0.94-1.20) relative to use of other AHMs. Associations approximated the null value when CCBs were considered by duration of use, length of action, or drug class. Conclusions: We provide additional evidence that CCBs do not influence breast cancer risk in postmenopausal women. Impact: The results from this study, which includes strong control for potential confounding factors, cast doubt on increases in risk with CCBs. Cancer Epidemiol Biomarkers Prev; 26(8); 1345-8.

UR - http://www.scopus.com/inward/record.url?scp=85026838190&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026838190&partnerID=8YFLogxK

U2 - 10.1158/1055-9965.EPI-17-0096

DO - 10.1158/1055-9965.EPI-17-0096

M3 - Article

C2 - 28765339

AN - SCOPUS:85026838190

VL - 26

SP - 1345

EP - 1348

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 8

ER -